Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Organisation › Details

AdBio Partners SAS (AFB)

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences – specifically in therapeutics-oriented projects. Its unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio partners has made 22 European investments in France, Belgium, Spain and Ireland – with two funds: AFB Seed Fund I and AFB FII. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team includes investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise. *AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. *

 

Period Start 2021-12-07 renamed
  Group AdBio Partners (Group)
  Predecessor Advent France Biotechnology SAS (AFB)
Products Industry venture capital
  Industry 2 BIOTECH
Persons Person Coutet, Matthieu (Advent France Biotechnology 201704 Managing Partner before Inserm Transfert)
  Person 2 Huriez, Alain (Advent France Biotechnology 201704 Managing Partner before Advent Life Sciences + TcLand + Neovacs)
     
Region Region Paris
  Country France
  Street 4 rue Thénard
  City 75005 Paris
  Tel +33-1-5681-6300
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: DiogenX SAS. (5/10/23). "Press Release: DiogenX Raises €27.5M Series A Financing to Advance Its First-in-Class Regenerative Treatment for Type 1 Diabetes Towards Clinical Development". Marseille.
     
   
Record changed: 2024-03-30

Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for AdBio Partners (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px




» top